Richard Pratley

Summary

Affiliation: University of Vermont
Country: USA

Publications

  1. ncbi request reprint The evolving role of inflammation in obesity and the metabolic syndrome
    Yong Ho Lee
    Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology and Metabolism, Department of Medicine, University of Vermont College of Medicine, FAHC UHC Arnold 3412, One South Prospect Street, Burlington, VT 05401, USA
    Curr Diab Rep 5:70-5. 2005
  2. ncbi request reprint Metabolic syndrome: why the controversy?
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 05465, USA
    Curr Diab Rep 7:56-9. 2007
  3. pmc One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
    R Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 04556, USA
    Int J Clin Pract 65:397-407. 2011
  4. ncbi request reprint Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
    R E Pratley
    University of Vermont College of Medicine, Burlington, VT 05401, USA
    Horm Metab Res 38:423-8. 2006
  5. doi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
    R E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 05446, USA
    Diabetes Obes Metab 11:167-76. 2009
  6. ncbi request reprint Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Richard E Pratley
    University of Vermont College of Medicine, Diabetes and Metabolism Translational Medicine Unit, Colchester Research Facility 110C, 208 Park Street, Colchester, VT 05446, USA
    Expert Opin Pharmacother 10:503-12. 2009
  7. pmc Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes
    Richard E Pratley
    Department of Medicine, Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, University of Vermont College of Medicine, Burlington, USA
    Medscape J Med 10:171. 2008
  8. doi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Given C331, 89 Beaumont Avenue, Burlington, VT 05405, USA
    Curr Med Res Opin 25:2361-71. 2009
  9. ncbi request reprint Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes
    Richard Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont, College of Medicine, Burlington, Vermont 05405, USA
    Endocrinol Metab Clin North Am 35:6-11; discussion 17-19. 2006
  10. doi request reprint Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, Department of Medicine, College of Medicine, University of Vermont Burlington, Vermont 05403, USA
    J Am Geriatr Soc 57:2011-9. 2009

Detail Information

Publications38

  1. ncbi request reprint The evolving role of inflammation in obesity and the metabolic syndrome
    Yong Ho Lee
    Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology and Metabolism, Department of Medicine, University of Vermont College of Medicine, FAHC UHC Arnold 3412, One South Prospect Street, Burlington, VT 05401, USA
    Curr Diab Rep 5:70-5. 2005
    ..An improved understanding of the role of adipose tissue in the activation of inflammatory pathways may suggest novel treatment and prevention strategies aimed at reducing obesity-associated morbidities and mortality...
  2. ncbi request reprint Metabolic syndrome: why the controversy?
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 05465, USA
    Curr Diab Rep 7:56-9. 2007
    ..However, recent articles have called the clinical use of the metabolic syndrome into question. In this review, some of these concerns and counterarguments for the continued use of the metabolic syndrome are reviewed...
  3. pmc One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
    R Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 04556, USA
    Int J Clin Pract 65:397-407. 2011
    ....
  4. ncbi request reprint Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes
    R E Pratley
    University of Vermont College of Medicine, Burlington, VT 05401, USA
    Horm Metab Res 38:423-8. 2006
    ..Concomitant improvements in beta-cell function were also observed. Subjects with higher baseline HbA1c levels showed greater response...
  5. doi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy
    R E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT 05446, USA
    Diabetes Obes Metab 11:167-76. 2009
    ..To evaluate the efficacy and safety of alogliptin, a potent and highly selective dipeptidyl peptidase-4 (DPP-4) inhibitor, in combination with glyburide in patients with type 2 diabetes inadequately controlled by sulphonylurea monotherapy...
  6. ncbi request reprint Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes
    Richard E Pratley
    University of Vermont College of Medicine, Diabetes and Metabolism Translational Medicine Unit, Colchester Research Facility 110C, 208 Park Street, Colchester, VT 05446, USA
    Expert Opin Pharmacother 10:503-12. 2009
    ..Alogliptin is a potent, highly selective dipeptidyl peptidase-4 inhibitor now undergoing clinical testing to support a new drug application for the treatment of type 2 diabetes...
  7. pmc Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes
    Richard E Pratley
    Department of Medicine, Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, University of Vermont College of Medicine, Burlington, USA
    Medscape J Med 10:171. 2008
    ..Glucoregulatory agents that target the incretin system have recently been developed, and the place of these drugs in the treatment of type 2 diabetes can be assessed based on a growing body of clinical data...
  8. doi request reprint Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Given C331, 89 Beaumont Avenue, Burlington, VT 05405, USA
    Curr Med Res Opin 25:2361-71. 2009
    ..To evaluate the efficacy and safety of alogliptin in patients with type 2 diabetes inadequately controlled by therapy with a thiazolidinedione (TZD)...
  9. ncbi request reprint Islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes
    Richard Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont, College of Medicine, Burlington, Vermont 05405, USA
    Endocrinol Metab Clin North Am 35:6-11; discussion 17-19. 2006
  10. doi request reprint Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, Department of Medicine, College of Medicine, University of Vermont Burlington, Vermont 05403, USA
    J Am Geriatr Soc 57:2011-9. 2009
    ..To compare the efficacy and safety of alogliptin, a dipeptidyl peptidase-4 (DPP-4) enzyme inhibitor, in elderly (> or =65) and younger (<65) patients with type 2 diabetes mellitus...
  11. doi request reprint Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial
    Richard E Pratley
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT, USA
    Lancet 375:1447-56. 2010
    ....
  12. ncbi request reprint Management of type 2 diabetes in treatment-naive elderly patients: benefits and risks of vildagliptin monotherapy
    Richard E Pratley
    Vermont College of Medicine, Burlington, USA
    Diabetes Care 30:3017-22. 2007
    ..The purpose of this study was to evaluate the efficacy and safety of vildagliptin in elderly patients with type 2 diabetes...
  13. pmc Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes
    DAVID A D'ALESSIO
    University of Cincinnati, Department of Internal Medicine, Division of Endocrinology, Diabetes and Metabolism, ML 0547, Cincinnati, Ohio 45267, USA
    J Clin Endocrinol Metab 94:81-8. 2009
    ..Objective: The objective of the study was to examine the effects of DPP-4 inhibition on fasting islet function...
  14. ncbi request reprint The PROactive trial (PROspective pioglitAzone Clinical Trial In macroVascular Events): what does it mean for primary care physicians?
    Vanitha Singaram
    Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, USA
    Diab Vasc Dis Res 4:237-40. 2007
    ..The PROactive trial was undertaken to test whether treatment with the thiazolidinedione pioglitazone could decrease the number of CVD events in high-risk patients with T2DM...
  15. ncbi request reprint Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes
    Richard E Pratley
    University of Vermont College of Medicine, Burlington, VT 05405, USA
    Curr Med Res Opin 23:919-31. 2007
    ..Drugs that inhibit dipeptidyl peptidase-4 (DPP-4), a ubiquitous enzyme that rapidly inactivates both GLP-1 and GIP, increase active levels of these hormones and, in doing so, improve islet function and glycemic control in T2DM...
  16. pmc Effect of ovarian suppression with gonadotropin-releasing hormone agonist on glucose disposal and insulin secretion
    Michael J Toth
    Department of Medicine and Obstetrics and Gynecology, University of Vermont, Burlington, VT 05405, USA
    Am J Physiol Endocrinol Metab 294:E1035-45. 2008
    ..Our data do, however, support a role for ovarian hormones in the regulation of plasma adiponectin levels...
  17. doi request reprint Expanding treatment options for type 2 diabetes: the old and the new
    Richard E Pratley
    Department of Medicine, University of Vermont College of Medicine, Colchester Research Facility 110C, Colchester, Vermont 05446, USA
    Diabetes Educ 35:4S-11S. 2009
    ....
  18. pmc Sexually dimorphic diet-induced insulin resistance in obese tissue inhibitor of metalloproteinase-2 (TIMP-2)-deficient mice
    Diane M Jaworski
    Department of Anatomy and Neurobiology, University of Vermont College of Medicine, 149 Beaumont Avenue, HSRF 418, Burlington, Vermont 05405, USA
    Endocrinology 152:1300-13. 2011
    ....
  19. ncbi request reprint Abdominal obesity and cardiovascular disease risk: the emerging role of the adipocyte
    Yong Ho Lee
    Diabetes and Metabolism Translational Medicine Unit, Division of Endocrinology, Diabetes and Metabolism, Department of Medicine, University of Vermont College of Medicine, Burlington, VT 05405, USA
    J Cardiopulm Rehabil Prev 27:2-10. 2007
  20. doi request reprint Alternative and complementary treatments for metabolic syndrome
    Mariya Power
    Nutrition and Food Science Department, University of Vermont, Colchester Research Facility, Room 110, 208 South Park Drive, Colchester, VT 05446, USA
    Curr Diab Rep 11:173-8. 2011
    ..However, more clinical trials are needed to determine the dose and duration of such treatments to make specific recommendations for populations with metabolic syndrome...
  21. ncbi request reprint Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes
    Susanne Trost
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, One South Prospect Street, Burlington, VT 05401, USA
    Curr Diab Rep 6:47-54. 2006
    ..Weight loss, metformin, and thiazolidinediones ameliorate insulin resistance and decrease concentrations of PAI-1. Thus, they may lower risk in patients with the metabolic syndrome...
  22. doi request reprint Plasma amyloid-beta peptide levels correlate with adipocyte amyloid precursor protein gene expression in obese individuals
    Yong Ho Lee
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, VT, USA
    Neuroendocrinology 90:383-90. 2009
    ..In this study, we aimed to investigate the relation between adipocyte APP expression and plasma Abeta peptide levels...
  23. doi request reprint Amyloid precursor protein expression is upregulated in adipocytes in obesity
    Yong Ho Lee
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont, USA
    Obesity (Silver Spring) 16:1493-500. 2008
    ..These data suggest a possible role for APP and/or Abeta in the development of obesity-related insulin resistance and adipose tissue inflammation...
  24. ncbi request reprint On rendering continuous glucose monitoring ready for prime time in the cardiac care unit
    Michaelanne Rowen
    Cardiovascular Research Institute, University of Vermont College of Medicine, Burlington, Vermont 05446, USA
    Coron Artery Dis 18:405-9. 2007
    ..We therefore explored the potential value of use of a continuous glucose monitoring system to enhance glycemic control in the CCU and sought to identify pitfalls that could be overcome to increase its utility...
  25. doi request reprint Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus
    Matthew P Gilbert
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont 05405, USA
    Eur J Intern Med 20:S309-18. 2009
    ....
  26. doi request reprint Efficacy and safety of incretin-based therapies in patients with type 2 diabetes mellitus
    Matthew P Gilbert
    Diabetes and Metabolism Translational Medicine Unit, University of Vermont College of Medicine, Burlington, Vermont 05405, USA
    Am J Med 122:S11-24. 2009
    ....
  27. ncbi request reprint Increased plasminogen activator inhibitor type-1 (PAI-1) in the heart as a function of age
    Burton E Sobel
    University of Vermont, Cardiovascular Research Institute, Colchester Research Facility, 208 South Park Drive, Colchester, VT 05446, USA
    Life Sci 79:1600-5. 2006
    ....
  28. ncbi request reprint Insulin resistance increases PAI-1 in the heart
    Burton E Sobel
    University of Vermont, Cardiovascular Research Institute Burlington, VT, USA
    Biochem Biophys Res Commun 346:102-7. 2006
    ..Such increases may contribute to fibrosis and diastolic dysfunction typical late after infarction in patients with insulin resistance...
  29. ncbi request reprint The PROactive Study: pioglitazone in the secondary prevention of macrovascular events in patients with type 2 diabetes
    Richard E Pratley
    Curr Diab Rep 6:45-6. 2006
  30. ncbi request reprint Beta-cell function in mild type 2 diabetic patients: effects of 6-month glucose lowering with nateglinide
    Andrea Mari
    Institute of Biomedical Engineering, National Research Council, Corso Stati Uniti 4, 35127 Padua, Italy
    Diabetes Care 28:1132-8. 2005
    ....
  31. ncbi request reprint Endogenous glucose production, insulin sensitivity, and insulin secretion in normal glucose-tolerant Pima Indians with low birth weight
    Norbert Stefan
    The Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ, USA
    Metabolism 53:904-11. 2004
    ..We conclude that interaction of multiple defects may contribute to increased susceptibility to type 2 diabetes among individuals with LBW...
  32. ncbi request reprint Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians
    Christian Weyer
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 4212 N 16th Street Rm 5 41, Phoenix, AZ 85016, USA
    Atherosclerosis 161:233-42. 2002
    ..Thus, obesity and insulin resistance appear to be associated with low-grade inflammation and endothelial dysfunction, respectively, even in an obesity- and diabetes-prone population with relatively low propensity for atherosclerosis...
  33. ncbi request reprint Plasma adiponectin concentration is associated with skeletal muscle insulin receptor tyrosine phosphorylation, and low plasma concentration precedes a decrease in whole-body insulin sensitivity in humans
    Norbert Stefan
    Clinical Diabetes and Nutrition Section, National Institutes of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes 51:1884-8. 2002
    ..Prospectively, low plasma adiponectin concentration at baseline precedes a decrease in insulin sensitivity. Our data indicate that adiponectin plays an important role in regulation of insulin sensitivity in humans...
  34. ncbi request reprint High alanine aminotransferase is associated with decreased hepatic insulin sensitivity and predicts the development of type 2 diabetes
    Barbora Vozarova
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona, USA
    Diabetes 51:1889-95. 2002
    ..Our findings indicate that high ALT is a marker of risk for type 2 diabetes and suggest a potential role of the liver in the pathogenesis of type 2 diabetes...
  35. ncbi request reprint UCP5/BMCP1 transcript isoforms in human skeletal muscle: relationship of the short-insert isoform with lipid oxidation and resting metabolic rates
    Xiaolin Yang
    Clinical Diabetes and Nutrition Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Mol Genet Metab 75:369-73. 2002
    ..38, P=0.02, adjusted for age, sex, fat mass, and fat-free mass) and lipid oxidation rate (adjusted for age, sex, and percent body fat) during a euglycemic clamp with infusion of insulin at a physiologic concentration (r=0.42, P=0.01)...
  36. ncbi request reprint Progression from IGT to type 2 diabetes mellitus: the central role of impaired early insulin secretion
    Richard E Pratley
    Novartis Pharmaceuticals Corporation, Clinical Research and Development, Diabetes and Obesity Section, One Health Plaza, East Hanover, NJ 07936, USA
    Curr Diab Rep 2:242-8. 2002
    ..Other trials using pharmacologic agents to decrease insulin resistance and increase early insulin secretion are underway. Prevention remains the best hope for a long-term solutions to the worldwide epidemic of diabetes...
  37. ncbi request reprint Taste preferences and body weight changes in an obesity-prone population
    Arline D Salbe
    Clinical Diabetes and Nutrition Section, Phoenix Epidemiology and Clinical Research Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, AZ 85016, USA
    Am J Clin Nutr 79:372-8. 2004
    ..Taste preferences for highly palatable foods rich in sugar and fat may underlie the current epidemic of obesity...
  38. ncbi request reprint High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes
    Barbora Vozarova
    Clinical Diabetes and Nutrition Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Phoenix, Arizona 85016, USA
    Diabetes 51:455-61. 2002
    ..These findings are consistent with the hypothesis that a chronic activation of the immune system may play a role in the pathogenesis of type 2 diabetes...